The evidence that siRNA can be used for suppression of genes in different mammalian cells has attracted great attention as a new possibility of treatment for many diseases.However, for therapeutic application of siRNA is necessary to develop an effective and non-toxic delivery system, allowing uptake cell and prevent degradation by enzymes. One of the dosage forms that have been widely used in literature in order to protect and prolong the release of drugs and peptides are the formulations that form in situ gelling. Thus this project aims the pharmaceutical development of liquid crystalline formulations with gel formation in situ after subcutaneous administration to delivery siRNA, as well as the in vitro evaluation of their retention / release and toxicity. The specific objectives are: (1) Obtainment and characterization of liquid crystalline formulations that form gels in situ (2) Investigation of in vitro release of siRNA from these systems, (3) In vivo studies using an animal model for evaluation of gel formation in situ and (4) Study of toxicity in an animal model. This project is important because provide the basis for the application of siRNA as a therapeutic agent to treat serious diseases where gene therapy with RNAi is a treatment perspective.
News published in Agência FAPESP Newsletter about the scholarship: